In the first of these studies, Estiar and colleagues analyzed tissue samples from 88 patients and found that NDRG3 was downregulated in patients with breast cancer, and that patients with a low tumor expression of NDRG3 had worse outcomes than those with a high NDRG3-expressing tumors [79]. This evidence concerns the gene NDRG3 and neoplasm.